Sign up to get each new magazine issue delivered to your inbox

January 2023

In the next issue, we kick off the new year with our predictions for the pharmaceutical and biotech sectors in 2023. The year will be marked with the entry of biosimilars to AbbVie’s blockbuster Humira and we take a look at the several competitors vying to gain the most profits as the anti-TNF drug gets edged off its position as the top-selling biologic in recent years.  


With the help of data, we will also take a look at trends in mergers and acquisitions over 2022, and what can be expected with deals in this space amidst the ongoing energy and financial crises.

EDITORIAL

Editor | Manasi Vaidya

Writers | Urtė Fultinavičiūtė, Irena Maragkou, Akosua Mireku, William Newton, Adam Zamecnik

Magazine Designer | Will Ingham
Graphic Designers | Anett Arc, Noemi Balint, Martina Labaiova, Tyrrell Lowe, Ashley McPherson
Lead Designer | John Hammond 

Publisher | Susanne Hauner

Advertising

Sales Manager | Tom McCormick
+44 207 8669440

Cover image: Composite. Credit: PremiumArt, Ardea-studio and Will Ingham

Pharma Technology Focus is powered by H5mag

Read past issues of Pharma Technology Focus HERE

Copyright 2022 NRi Digital, a trading division of Verdict Media Ltd. Registered office John Carpenter House, John Carpenter Street, London, EC4Y 0AN, UK. Company registration number 03171601. All rights reserved. No part of this publication may be reproduced in any form or by any means, electronic, photocopying or otherwise, without prior permission of the publisher and copyright owner. While every effort has been made to ensure the accuracy of this publication, the publisher accepts no responsibility for errors or omissions. The products and services advertised are those of individual authors and are not necessarily endorsed by or connected with the publisher. The opinions expressed in the articles within this publication are those of individual authors and not necessarily those of the publisher.

Go to article: Home | What Rishi Sunak can do for the UK pharma industry Go to article: In this issueGo to article: ContentsGo to article: CSafeGo to article: TripletreeGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: BEA TechnologiesGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: CommentGo to article: GSK speeds up the race to market first RSV vaccine for older adultsGo to article: Biden’s directive on foreign biotech investments impacts manufacturersGo to article: Novo Nordisk targets FDA approval for once-weekly insulin after Phase III dataGo to article: ‘Twindemic’ risks warrant immediate steps in Europe and the US Go to article: A game of two halves for Roche’s recently approved wet AMD assetsGo to article: Dr. Paul LohmannGo to article: NiproGo to article: In DepthGo to article: What Rishi Sunak can do for the UK pharma industryGo to article: Inside the European mass shift to data-driven health solutionsGo to article: Chronic drug shortages signal difficult outlook for cardiovascular careGo to article: Can gene therapies for haemophilia defend their high price tags?Go to article: Trial termination analysis unveils a silver lining for patient recruitmentGo to article: New dawn for the EU's joint procurement crisis responseGo to article: SkyepharmaGo to article: Bio Image Systems Inc.Go to article: In DataGo to article: The pharma industry found it easier to fill AI vacancies in Q3 2022 Go to article: Internet of things hiring levels in the pharma dropped in October 2022Go to article: Artificial intelligence hiring levels in the pharma dropped in October 2022Go to article: BaxterGo to article: EventsGo to article: Next issue